Century Therapeutics (IPSC) Accumulated Depreciation (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Accumulated Depreciation data on file, last reported at $51.6 million in Q1 2026.

• Quarterly Accumulated Depreciation rose 31.96% year-over-year to $51.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $51.6 million (up 31.96% YoY) and the FY2025 annual result came in at $48.6 million, up 34.78% from the prior year.
• Accumulated Depreciation advanced to $51.6 million in Q1 2026 per IPSC's latest filing, from $48.6 million in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $51.6 million in Q1 2026 and bottomed at $6.5 million in Q1 2022.
• The 5-year median for Accumulated Depreciation is $26.0 million (2024), against an average of $27.7 million.
• The widest annual swing landed in 2022, when Accumulated Depreciation jumped 156.24%; it then surged 31.96% in 2026.
• Tracing IPSC's Accumulated Depreciation over 5 years: stood at $13.7 million in 2022, then jumped by 67.25% to $22.8 million in 2023, then soared by 57.89% to $36.1 million in 2024, then soared by 34.78% to $48.6 million in 2025, then climbed by 6.18% to $51.6 million in 2026.
• Per Business Quant, the three latest IPSC Accumulated Depreciation figures stand at $51.6 million (Q1 2026), $48.6 million (Q4 2025), and $45.6 million (Q3 2025).

Peer Comparison